|
|||
|
Multiple Sclerosis Info
|
« Previous
Tuesday, February 26
Predictive markers for response to interferon therapy in patients with multiple sclerosis.
by
All About MS
on Tue 26 Feb 2008 12:00 AM CST
Prolonged therapy with interferon beta (IFNbeta) often leads to the development of anti-IFNbeta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and more »
Wednesday, February 6
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
by
All About MS
on Wed 06 Feb 2008 06:57 AM CST
Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced
that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium- enhancing lesions when daclizumab more »
Monday, February 4
FDA Approves Betaseron for Use After the First Event Suggestive of Multiple Sclerosis
by
All About MS
on Mon 04 Feb 2008 07:20 AM CST
The two-year study showed that treatment with Betaseron delayed the time to a second clinical event by one year compared to placebo. (1) BENEFIT is the only trial to demonstrate the more »
|
||
